Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Benedikt, M; Oulhaj, A; Rohrer, U; Manninger, M; Tripolt, NJ; Pferschy, PN; Aziz, F; Wallner, M; Kolesnik, E; Gwechenberger, M; Martinek, M; Nürnberg, M; Roithinger, FX; Steinwender, C; Widkal, J; Leiter, S; Zirlik, A; Stühlinger, M; Scherr, D; Sourij, H; von, Lewinski, D.
Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds.
NEJM Evid. 2024; 3(10):EVIDoa2400147
Doi: 10.1056/EVIDoa2400147
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Benedikt Martin
- Scherr Daniel
- von Lewinski Dirk
- Co-authors Med Uni Graz
- Aziz Faisal
- Kolesnik Ewald
- Manninger-Wünscher Martin
- Pferschy Peter
- Rohrer Ursula
- Sourij Harald
- Tripolt Norbert
- Wallner Markus
- Zirlik Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have beneficial pleiotropic effects, contributing to improved cardiovascular and renal outcomes for patients with and without diabetes. The impact of SGLT2is on arrhythmic burden remains largely unexplored through randomized trials. METHODS: In this multicenter, double-blind, randomized, placebo-controlled trial, we investigated the effects of ertugliflozin on arrhythmic burden among patients with heart failure with an ejection fraction less than 50%. All patients had an implantable cardioverter-defibrillator (ICD) with or without a cardiac resynchronization therapy device (CRT-D) and were randomized (1:1) to receive either ertugliflozin 5 mg once daily or placebo. The primary end point was the number of incident sustained (>30 seconds) ventricular tachycardia or ventricular fibrillation events from baseline to week 52. Secondary end points included the total number of non-sustained ventricular tachycardias, appropriate ICD therapies, changes in N-terminal pro-brain-type natriuretic peptide (NTproBNP) levels, and the number of heart failure hospitalizations. RESULTS: Randomization was prematurely terminated, after class IA guideline recommendations were published for SGLT2is in patients with heart failure regardless of the ejection fraction. The final analysis included 46 patients (11% of the originally planned sample size). The yearly rate of the primary end point was 3.5 (95% confidence interval [CI] 2.8 to 4.4) with ertugliflozin compared with 13.3 with placebo (95% CI 11.8 to 14.8; rate ratio 0.16, 95% CI 0.04 to 0.61; P<0.001). There were no apparent differences in appropriate ICD therapies, hospitalizations, NTproBNP levels, or predefined adverse and serious adverse events. CONCLUSIONS: Ertugliflozin reduced sustained ventricular tachycardia or ventricular fibrillation events in adults with heart failure and an ICD compared with placebo; however, our trial ended early and thus results should be interpreted with caution. (Funded by Investigator-initiated Studies Program of Merck Sharp & Dohme Corp and Pfizer; EudraCT number, 2020-002581-14; ClinicalTrials.gov number NCT04600921.).